KKR invests $65m in China deal

KKR & Co agreed yesterday to invest $65m (£40.7m) in China Cord Blood Corp, making it the global private equity firm’s first healthcare investment in China. KKR’s investment will give the firm about 24 per cent of China Cord Blood on a fully diluted basis. China Cord Blood, with a market cap of about $200m, would use the money to expand in China, analysts say.